Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NNMT | P40261 | 2/20 | 0.53 |
| ▸ | TNKS | O95271 | 5/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.45 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16432204 | 0.99 | MEN1 (0.56) | SLC18A3MEN1CYP2D6KMT2ANNMT | |
| Tert-Butyl Formate SCHEMBL28134989 | 0.89 | SLC18A3 (0.47) | SLC18A3MEN1CYP2D6KMT2ANNMT | |
| SCHEMBL9980653 | 0.81 | KMT2A (0.62) | SLC18A3MEN1CYP2D6KMT2AHRH3 | |
| SCHEMBL22003706 | 0.81 | MEN1 (0.54) | SLC18A3MEN1CYP2D6KMT2AHRH3 | |
| SCHEMBL29480726 | 0.81 | MEN1 (0.54) | SLC18A3MEN1CYP2D6KMT2AHRH3 | |
| SCHEMBL28049663 | 0.80 | SLC18A3 (0.60) | SLC18A3MEN1KMT2ANNMTTNKS | |
| SCHEMBL18228223 | 0.80 | SLC18A3 (0.60) | SLC18A3MEN1KMT2ANNMTTNKS | |
| SCHEMBL230405 | 0.77 | NPC1 (0.71) | MEN1CYP2D6KMT2ANPC1RAB9A | |
| SCHEMBL26094393 | 0.77 | KMT2A (0.53) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28853734 | 0.77 | SLC18A3 (0.57) | SLC18A3NNMTTNKSTNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | MERCK PATENT GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| EP-3371166-B1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9901577-B2 | Oxoquinazolinyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9809598-B2 | Heterocyclyl-butanamide derivatives | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| WO-2017076484-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | WO | disclosed |
| EP-3027598-B1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-3140295-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-3027598-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015169421-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015169421-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015014442-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015014442-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-8658131-B2 | Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | WASHINGTON UNIVERSITY (US) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | TNKS, TANK, TBKBP1 | SLC18A3 4802/4885MEN1 3993/4885CYP2D6 2103/4885 |
| US-20110311447-A1 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand | SIGMAR1, TMEM97, OPRM1 | SLC18A3 248/4885MEN1 3922/4885CYP2D6 548/4885 |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | TNKS, TANK, TBKBP1 | SLC18A3 4802/4885MEN1 3993/4885CYP2D6 2103/4885 |
| US-20160184310-A1 | OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | TANK, IRAK3, TNKS | SLC18A3 4383/4885MEN1 3932/4885CYP2D6 2112/4885 |
| US-20170073347-A1 | HETEROCYCLYL-BUTANAMIDE DERIVATIVES | TNKS, TANK, TBKBP1 | SLC18A3 4678/4885MEN1 4039/4885CYP2D6 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.